Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYH2066
- Development stage
- Phase 2
- Lead developer
- CSPC Ouyi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SYH2066 is an investigational oral small molecule antiviral candidate developed by CSPC Ouyi Pharmaceutical (a subsidiary of CSPC Pharmaceutical Group) for the treatment of respiratory syncytial virus (RSV) infection. The drug is designed to inhibit viral replication, addressing a significant unmet need in respiratory medicine, particularly for vulnerable populations such as infants and the elderly. As of early 2025, SYH2066 is in Phase 1 clinical development in China (CTR20253751), where it is being evaluated in a randomized, double-blind, placebo-controlled study to determine its safety, tolerability, and pharmacokinetic profile, as well as the effect of food on its bioavailability in healthy adult participants.
Beyond the preview
Go deeper on SYH2066.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYH2066.